Contact us
BioPulse Consulting, Inc.
Kyle Abuarjah | CEO
Phone: 609-529-9282
Email: [email protected]
Send a Message
BioPulsers
Meet the dedicated professionals who drive our success, bringing a wealth of expertise and passion to every project we undertake

Kyle Abuarjah
Founder & CEO

Dr. Suliman Al-Fayoumi
Scientific Advisor,
Clinical Pharmacology

Dr. Philip Oldfield
Scientific Advisor-Bioanalysis

Kyle Abuarjah
FOUNDER & CEO
Kyle Abuarjah has over 20 years of experience in the CRO industry in the Large Molecule arena. Kyle started BioPulse Consulting to serve an unmet need and provide a cost effective outsourcing model for both CROs/CDMOs and Biopharmaceutical companies. Prior to BioPulse, Kyle provided Business Development leadership for Primera Analytical Solutions, Alliance Pharma, CMIC, Charles River Laboratories, SGS Life Sciences, and Quest Diagnostics. In addition, Kyle provided leadership in building the Large Molecule Bioanalytical lab operation at CMIC (formerly JCL Bioassay USA). Kyle began his career on the bench as a Medical Laboratory Technologist in diagnostics. Then, joined the CRO industry and worked in different roles in Immunoassay bioanalysis including Project Management, Business Development, and as a Principal Investigator. Kyle received his BSc in Clinical Laboratory Sciences from the University of Texas Medical Branch at Galveston and received his Masters of Business Administration (MBA) from Athabasca University. Kyle is certified by the American Society of Clinical Pathology (ASCP) and a member of the American Association of Pharmaceutical Scientists (AAPS). In his free time, when there is a free time, Kyle spends his time with Prada (Ms. Parudi) the kitty office manager.

Dr. Suliman Al-Fayoumi
SCIENTIFIC ADVISOR- CLINICAL PHARMACOLOG
Dr. Suliman Al-Fayoumi is currently a senior Consultant with Nuventra supporting several small Biotech companies primarily based in USA. Prior to taking-up consulting in 2017 then joining Allucent in 2021, Dr. Al-Fayoumi served as Vice President of Translational Sciences and Clinical Pharmacology at Cell Therapeutics Biopharma Inc., a niche hematology-oncology company based in Seattle, WA between 2013-2017. Prior to joining CTI Biopharma, Dr. Al-Fayoumi served as Director of Preclinical and Clinical Pharmacology and Interim Head of Research at Acucela Inc., a niche Ophthalmology company based in Seattle, WA between 2010-2013. Prior to joining Acucela, Dr. Al-Fayoumi served as Associate Director of Global PK/PD within the DMPK Department at Novartis Pharmaceuticals (East Hanover, NJ), where he supported the Cardiovascular & Metabolism (CVM) Franchise between 2006-2010. Prior to Joining Novartis Pharmaceuticals, Dr. Al-Fayoumi served as Senior Clinical Pharmacology Reviewer at US FDA between 1999-2006 supporting GI, anticoagulants, anesthetics, addiction and dermatology Drug Product Divisions. While at FDA, Dr. Al-Fayoumi was the primary clinical pharmacology reviewer for several high profile drug applications such as Nexium, Prilosec OTC, Prevacid, Oxycontin, Ximelagatran, Asacol, Remicade, Lovenox, Innohep, Exjade, Propulsid, Etreva, Fabrazyme, Zegerid, Protonix, Lotronex and Zelnorm. Dr. Al-Fayoumi received several awards for outstanding support of and significant contributions to the achievement of excellence in FDA drug safety initiatives related to optimal dosing and lowest effective dose including CDER’s Frances O. Kelsey Drug Safety Excellence Award. Dr. Al-Fayoumi has a B.S. degree in Pharmacy from Jordan University of Science and Technology. Dr. Al-Fayoumi received a Ph.D. in Pharmacokinetics from the University of Florida (Gainesville, FL) in 1998, and MBA degree in International Business from Fairleigh Dickinson University (Madison, NJ) in 2009. Dr. Al-Fayoumi is a member of the American Diabetes Association (ADA), the American College of Clinical Pharmacology (ACCP), the American Society of Clinical Pharmacology and Therapeutics (ASCPT), the American Association of Pharmaceutical Sciences (AAPS), European Hematology Association (EHA), and The American Society of Clinical Oncology (ASCO).

Dr. Philip Oldfield
Scientific Advisor-Bioanalysis
Dr. Philip Oldfield started his scientific career in 1974 in the Clinical Biochemistry Department at the Royal Postgraduate Medical School, Hammersmith Hospital London, England. Since then he has obtained three degrees; including a D.Phil obtained in 1982. The subject of his research thesis was “Proteolytic Control and Rheumatoid Disease”. In 1986 he was given the Baker Award for his work on Digoxin-Like-Immunoreactive-Substances. Dr Oldfield has had over 25 years experience in service to the pharmaceutical and biopharmaceutical industry specializing in LBA techniques and Good Laboratory Practice. Dr Oldfield is an Associate Member of the Royal College of Pathologists, a Fellow of the Royal Society of Chemistry, and a Member of the American Association of Pharmaceutical Scientists (currently the Past Chair of the Ligand Binding Assay Bioanalytical Focus Group). In conjunction with BioPulse, Dr Oldfield operates Philip Oldfield Bioanalytical Consulting where he provides strategic bioanalytical consulting with a commitment to quality focusing on biological and oligonucleotide therapeutics. Prior to that, Dr Oldfield was Scientific Director at Charles River Laboratories where he managed the scientific and technical operation for the Immunoassay group. In addition, he likes to maintain a link with the local universities, and has been involved in supervising postgraduate students, as well the occasional lecture. He is currently involved as a committee member to organize symposia and workshops as part of the Drug Development Program Course at the University of McGill.
We are Committed to You
We are a group of veteran scientists, with over 20 years of experience in the Contract Research Organizations (CRO) and Biopharma space, that came together to redefine business development. We have seen relationships prosper, deteriorate, programs discontinue, and you can say “we’ve seen the good, the bad, and the ugly.” The time has come to change that.
The BioPulse team has wealth of expertise in science and regulatory affairs and most importantly we understand that finding that symbiotic and synergistic relationship with a partner CRO is challenging. BioPulse was established to save you time and effort when looking and finding the right CRO that can support your drug development programs.
Your BioPulsers will not stop to bring you unparalleled service and an entirely customized process that will ultimately save you time and effort.
How we can help:
- Value-added service model
- Single point of contact
- Intimate communication
- Guidance: scientific and regulatory
- Connect you with a prequalified CRO within our vast network
- Provide you with competitive and comprehensive proposals
- One stop shop for all of your drug development needs